What is Xttrium Laboratories?
With a legacy spanning over eight decades, Xttrium Laboratories operates as a family-owned enterprise specializing in the development and distribution of high-quality antiseptic solutions. The company is widely recognized for its flagship oral rinse products, such as Dyna-Hex 2% and Dyna-Hex 4%, which serve as critical components in clinical and consumer health environments. Beyond its proprietary product line, Xttrium provides robust contract manufacturing services, offering specialized production capabilities to a diverse array of national clients. This dual-model approach allows the company to maintain high standards of quality control while adapting to the evolving demands of the pharmaceutical and hygiene sectors.
How much funding has Xttrium Laboratories raised?
Xttrium Laboratories has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Xttrium Laboratories
PPP
Public-Private Partnership
What's next for Xttrium Laboratories?
The recent influx of capital is expected to catalyze Xttrium Laboratories' growth trajectory, particularly in the realm of manufacturing efficiency and market reach. As the company navigates the complexities of the current healthcare environment, this funding will likely support the modernization of its production facilities and the scaling of its contract manufacturing division. By prioritizing innovation in antiseptic formulation and supply chain resilience, Xttrium is poised to capture additional market share, reinforcing its status as a cornerstone of the antiseptic manufacturing industry. Future strategic initiatives will likely focus on diversifying its product portfolio and deepening its integration into national healthcare distribution networks.
See full Xttrium Laboratories company page
